{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-301185","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.706111+00:00","generated_at":"2026-06-07T08:53:50.073469+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AbbVie extends option for Aldeyra's reproxalap with $5M fee","bullets":["AbbVie paid $5M non-refundable fee to extend option period for reproxalap co-development license.","Exercise period now until 10 business days after FDA approval or 18 months from Oct 31, 2023.","Option fee will be credited against upfront cash if License Agreement is signed.","Reproxalap is Aldeyra's NDA-stage treatment for dry eye disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-301185","json":"https://secwatch.observer/filing/0001193125-23-301185.json","markdown":"https://secwatch.observer/filing/0001193125-23-301185.md","text":"https://secwatch.observer/filing/0001193125-23-301185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/0001193125-23-301185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/d603612d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:53:50.073469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}